clinical trial · NCT06487078
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
ALK+ Non-Small-Cell Lung CarcinomaLorlatinib
brief summary
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context
started
Jan 20, 2025
primary completion
Nov 30, 2028
completion
Nov 30, 2028
last updated
May 6, 2026
official title
LOREA : ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF LORLATINIB IN UNTREATED ALK-POSITIVE NSCLC PATIENTS IN A FRENCH NON INTERVENTIONAL STUDY
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol